Teva Pharmaceutical Industries Ltd's stock had its IPO on March 26, 1990, making it an older stock than 84.63% of US equities in our set.
With a price/earnings ratio of 2,388.79, Teva Pharmaceutical Industries Ltd P/E ratio is greater than that of about 99.63% of stocks in our set with positive earnings.
Teva Pharmaceutical Industries Ltd's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 25.16%, greater than the shareholder yield of 89.23% of stocks in our set.
Stocks that are quantitatively similar to TEVA, based on their financial statements, market capitalization, and price volatility, are HAS, JHX, OTEX, WAB, and AIMC.
TEVA's SEC filings can be seen here. And to visit Teva Pharmaceutical Industries Ltd's official web site, go to www.tevapharm.com.
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA) Company Bio
Teva Pharmaceuticals manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. The company was founded in 1901 and is based in Petach Tikva, Israel.
TEVA Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Teva Pharmaceutical Industries Ltd. To summarize, we found that Teva Pharmaceutical Industries Ltd ranked in the 12th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 86.83%. As for the metrics that stood out in our discounted cash flow analysis of Teva Pharmaceutical Industries Ltd, consider:
Its compound free cash flow growth rate, as measured over the past 5.49 years, is -0.24% -- higher than only 6% of stocks in our DCF forecasting set.
26% of the company's capital comes from equity, which is greater than merely 11.62% of stocks in our cash flow based forecasting set.
As a business, Teva Pharmaceutical Industries Ltd experienced a tax rate of about 0% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than just 0% of stocks generating free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Teva Pharmaceutical Industries Ltd? See BLFS, IDXX, PCRX, ELAN, and EW.
NEW YORK, Sept. 27, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Teva Pharmaceuticals Industries Limited (“Teva” or the “Company”) (NYSE: TEVA) and certain of its officers. The class action, filed in United States District Court for the Eastern District of Pennsylvania, and docketed under 20-cv-04660, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise, acquired Teva securities between October 29, 2015 and August 18, 2020, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 pr...
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Teva Pharmaceuticals Industries Limited (NYSE: TEVA) between October 29, 2015 and August 18, 2020, inclusive (the "Class Period"). The lawsuit seeks to recover damages for Teva investors under the federal securities laws.
Renewed interest in emerging biotechnology companies lifted Sorento Therapeutics (NASDAQ:SRNE) recently. Excessive bearish volumes against the stock could squeeze them out further. If Sorrento continues to post positive news in its drug and testing developments on the novel coronavirus, then SRNE stock may keep rising.Source: Shutterstock At a 34.3% short float, the bearish bet on Sorrento is getting too crowded.The company posted a pair of news releases that caught investor attention. On Sept. 17, the company received U.S. Food and Drug Administration approved its Phase 1 clinical trial of STI-1499. COVI-GUARD is a neutralizing antibody for treating hospitalized Covid-19 patients.InvestorPlace - Stock Market News, Stock Advice & Trading TipsSorrento previously posted preclinical studie...